Î¥ÏÎ¿ÏÏÎ³Î¹ÎºÎ® Î±ÏÏÏÎ±ÏÎ·

More documents

Recommendations

Info

19284 ΕΦΗΜΕΡΙΣ ΤΗΣ ΚΥΒΕΡΝΗΣΕΩΣ (ΤΕΥΧΟΣ ΔΕΥΤΕΡΟ) 3816 ATC / . DDD MON 2721902 02 OXALIPLATIN/HOSPC/S.SOL.IN 5MG/ML BTx1 VIAL x20 ML HOSPIRA UK LIMITE 0.010504 G 9.521 2726501 02 OXALIPLATIN/TEVAC/S.SOL.IN 5MG/ML BTx1VIALx50MG/10ML TEVA PHARMA B.V., 0.010504 G 4.760 2726501 03 OXALIPLATIN/TEVAC/S.SOL.IN 5MG/ML BTx1VIALx100MG/20ML TEVA PHARMA B.V., 0.010504 G 9.521 2773401 01 OXALIPLATINE/GENPD.SOL.INF 5MG/1ML BTx1 VIAL x 50 MG GENERICS PHARMA 0.010504 G 4.760 2773401 07 OXALIPLATINE/GENPD.SOL.INF 5MG/1ML BTx1 VIAL x100 MG GENERICS PHARMA 0.010504 G 9.521 2818901 01 OXALIPROL C/S.SOL.IN 5MG/1ML BTx1 VIAL x 10ML NOVENDIA 0.010504 G 4.760 2818901 02 OXALIPROL C/S.SOL.IN 5MG/1ML BTx1 VIAL x 20ML NOVENDIA 0.010504 G 9.521 2787001 01 PLAXITIN PD.SOL.INF 5MG/ML BTx1VIAL( 50mg/VIAL) EBEWE PHARMA GE 0.010504 G 4.760 2787001 02 PLAXITIN PD.SOL.INF 5MG/ML BTx1VIAL(100mg/VIAL) EBEWE PHARMA GE 0.010504 G 9.521 2818901 03 OXALIPROL C/S.SOL.IN 5MG/1ML BTx1 VIAL x 40ML NOVENDIA 0.010504 G 19.041 2774601 01 OXALTINA PD.SOL.INF 5MG/1ML BT x 1 VIAL x 50 MG 0.010504 G 4.760 2787001 03 PLAXITIN PD.SOL.INF 5MG/ML BTx1VIAL(150mg/VIAL) EBEWE PHARMA GE 0.010504 G 14.281 2787701 01 OXALIPLATIN/KABI C/S.SOL.IN 5MG/ML VIALx10MLx50MG FRESENIUS KABI ON 0.010504 G 4.760 2787701 02 OXALIPLATIN/KABI C/S.SOL.IN 5MG/ML VIALx20MLx100MG FRESENIUS KABI ON 0.010504 G 9.521 2898801 01 RECTOXAL PD.SOL.INF 5MG/ML (50MG/V BTx1VIALx50MG A.E. 0.010504 G 4.760 2898801 02 RECTOXAL PD.SOL.INF 5MG/ML (50MG/V BTx1VIALx100MG A.E. 0.010504 G 9.521 L01XC -M L01XC G1 -M / ( ) L01XC02 RITUXIMAB 2356401 01 MABTHERA C/S.SOL.IN 100MG/10ML VIAL BTx2VIALSx10ML ROCHE REGISTRAT 0.092679 G 2.158 2356402 01 MABTHERA CS.INJ.SOL 500MG/50ML BTx1VIALx50ML ROCHE REGISTRAT 0.092679 G 5.395 L01XC G2 -M / ( ) L01XC03 TRASTUZUMAB 2457301 01 HERCEPTIN PD.C.SO.IN 150 MG/VIAL BTx1VIAL(GLASS) ROCHE REGISTRAT 0.02 G 7.500 L01XC G4 -M / ( ) L01XC07 BEVACIZUMAB 2676901 01 AVASTIN C/S.SOL.IN 100 MG/4 ML BT x 1 VIAL x 4 ML ROCHE REGISTRAT 0.0375 G 2.667 2676902 01 AVASTIN C/S.SOL.IN 400 MG/16 ML BT x 1 VIAL x 16 ML ROCHE REGISTRAT 0.0375 G 10.667
ΕΦΗΜΕΡΙΣ ΤΗΣ ΚΥΒΕΡΝΗΣΕΩΣ (ΤΕΥΧΟΣ ΔΕΥΤΕΡΟ) 19285 3816 ATC / . DDD MON L01XC G5 -M / ( ) L01XC08 PANITUMUMAB 2815001 01 VECTIBIX C/S.SOL.IN 100MG/5ML VIAL BT x 1 VIAL x 5 ML AMGEN EUROPE BV 0.03 G 3.333 2815003 01 VECTIBIX C/S.SOL.IN 400MG/20ML VIAL BT x 1 VIAL x 20 ML AMGEN EUROPE BV 0.03 G 13.333 L01XC G6 -M / ( ) L01XC10 OFATUMUMAB 2940301 01 ARZERRA C/S.SOL.IN 20MG/ML BTx3 VIALSx 5ML GLAXO GROUP LTD 0.285714 G 1.050 2940301 02 ARZERRA C/S.SOL.IN 20MG/ML BTx10 VIALSx 5ML GLAXO GROUP LTD 0.285714 G 3.500 L01XD - / ( ) L01XD04 5-AMINOLEVULINIC ACID HYDROCHLORIDE 2934901 01 GLIOLAN PD.ORA.SOL 30MG/ML BTx1VIALx1,5G MEDAC GESELLSCH 1 TE 1.000 ( ) L01XD01 PORFIMER SODIUM 2395302 01 PHOTOFRIN PD.INJ.SOL 75MG/VIAL BT x 1 VIAL GALENICA 0.14 G 0.536 L01XE - L01XE G1 - / ( ) L01XE01 IMATINIB MESILATE 2534403 02 GLIVEC F.C.TAB 100MG/TAB BTX60 NOVARTIS EUROPHA 0.5 G 12.000 2534404 02 GLIVEC F.C.TAB 400MG/TAB BTX30 NOVARTIS EUROPHA 0.5 G 24.000 L01XE G2 - /
Page 1 and 2:
18959 ΕΦΗΜΕΡΙΣ ΤΗΣ ΚΥ
Page 3 and 4:
ΕΦΗΜΕΡΙΣ ΤΗΣ ΚΥΒΕΡ
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276: ΕΦΗΜΕΡΙΣ ΤΗΣ ΚΥΒΕΡ
Page 325: ΕΦΗΜΕΡΙΣ ΤΗΣ ΚΥΒΕΡ
show all

Î¥ÏÎ¿Ï ÏÎ³Î¹ÎºÎ® Î±ÏÏÏÎ±ÏÎ·

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?

Î¥ÏÎ¿ÏÏÎ³Î¹ÎºÎ® Î±ÏÏÏÎ±ÏÎ·